Studies on a complex mechanism for the activation of plasminogen by kaolin and by chloroform: the participation of Hageman factor and additional cofactors
Open Access
- 1 October 1969
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 48 (10) , 1786-1801
- https://doi.org/10.1172/jci106145
Abstract
As demonstrated by others, fibrinolytic activity was generated in diluted, acidified normal plasma exposed to kaolin, a process requiring Hageman factor (Factor XII). Generation was impaired by adsorbing plasma with glass or similar agents under conditions which did not deplete its content of Hageman factor or plasminogen. The defect could be repaired by addition of a noneuglobulin fraction of plasma or an agent or agents eluted from diatomaceous earth which had been exposed to normal plasma. The restorative agent, tentatively called Hageman factor-cofactor, was partially purified by chromatography and had an apparent molecular weight of approximately 165,000. It could be distinguished from plasma thromboplastin antecedent (Factor XI) and plasma kallikrein, other substrates of Hageman factor, and from the streptokinase-activated pro-activator of plasminogen. Evidence is presented that an additional component may be needed for the generation of fibrinolytic activity in mixtures containing Hageman factor, HF-cofactor, and plasminogen. The long-recognized generation of plasmin activity in chloroform-treated euglobulin fractions of plasma was found to be dependent upon the presence of Hageman factor. Whether chloroform activation of plasminogen requires Hageman factor-cofactor was not determined, but glass-adsorbed plasma, containing Hageman factor and plasminogen, did not generate appreciable fibrinolytic or caseinolytic activity. These studies emphasize the complex nature of the mechanisms which lead to the generation of plasmin in human plasma.Keywords
This publication has 39 references indexed in Scilit:
- THE INHIBITION OF PLASMIN, PLASMA KALLIKREIN, PLASMA PERMEABILITY FACTOR, AND THE C'1r SUBCOMPONENT OF THE FIRST COMPONENT OF COMPLEMENT BY SERUM C'1 ESTERASE INHIBITORThe Journal of Experimental Medicine, 1969
- ABOLITION OF PERMEABILITY-ENHANCING PROPERTIES OF HAGEMAN FACTOR BY SPECIFIC ANTISERUM1967
- IMMUNOLOGIC DEMONSTRATION OF A DEFICIENCY OF HAGEMAN FACTOR-LIKE MATERIAL IN HAGEMAN TRAIT1967
- HAGEMAN FACTOR IN THE FIBRINOLYTIC SYSTEMThe Lancet, 1965
- ACTIVATION OF HAGEMAN FACTOR BY SOLUTIONS OF ELLAGIC ACID.1964
- The Purification of Activated Hageman Factor (Activated Factor XII)*Biochemistry, 1962
- Selective Inactivation of the Plasminogen Contaminant in ThrombinNature, 1960
- Induction of Fibrinolysis By Venous ObstructionAngiology, 1960
- STUDIES ON THE THROMBOLYTIC ACTIVITY OF HUMAN PLASMA *Journal of Clinical Investigation, 1960
- A Plasminogen Activator in Spontaneously Active Human Blood.Experimental Biology and Medicine, 1953